Impact of IL-4/IL-13 Blockade with Dupilumab on the Microbiome in Type 2 Inflammatory Diseases: A Systematic Review
Clinical Snapshot
PICO Framework
| P — Population | Patients with type 2 inflammatory diseases (primarily atopic dermatitis, chronic rhinosinusitis with nasal polyps, NSAID-exacerbated respiratory disease) |
| I — Intervention | Dupilumab (IL-4/IL-13 blockade) |
| C — Comparator | Pre-treatment baseline or control groups |
| O — Outcomes | Microbiome changes across anatomical sites (skin, sinonasal tract, gut) including microbial diversity, specific taxa abundance, and metabolic pathways |
Bottom Line
This systematic review of 15 studies demonstrates that dupilumab produces compartment-specific microbiome changes in type 2 inflammatory diseases. The strongest evidence comes from skin studies showing consistent reductions in pathogenic Staphylococcus aureus and increased microbial diversity in atopic dermatitis patients. Sinonasal studies suggest beneficial shifts toward healthier microbial communities, while gut microbiome evidence remains limited. These findings support dupilumab's therapeutic mechanism through IL-4/IL-13 blockade and restoration of microbial homeostasis. However, the evidence is primarily observational and lacks quantitative synthesis. While promising for understanding drug mechanisms, microbiome changes are not yet ready for clinical biomarker use. Australian clinicians can be reassured that dupilumab's benefits extend beyond symptom control to include restoration of healthy microbial communities, particularly in skin and sinonasal sites.
Key Findings
P Value: Not reported in abstract
Effect Size: Consistent reduction in Staphylococcus aureus and increased microbial diversity in skin studies
Primary Outcome: Compartment-specific microbiome changes with dupilumab treatment
Nnt Or Sensitivity: Microbiome signatures as potential biomarkers require further validation
Confidence Interval: Not reported in abstract
Clinical Application
Microbiome monitoring not routinely available in clinical practice; research findings support dupilumab's mechanism of action Dupilumab PBS-listed for severe atopic dermatitis and asthma; findings support therapeutic rationale and may inform future biomarker development Australian patients with atopic dermatitis, chronic rhinosinusitis with nasal polyps, and NSAID-exacerbated respiratory disease receiving dupilumab
Abstract
PURPOSE OF REVIEW: To systematically review current evidence on microbiota changes associated with dupilumab treatment across different anatomical sites in type 2 inflammatory diseases. RECENT FINDINGS: Fifteen studies were included, comprising two randomized trials and thirteen observational studies, mostly in atopic dermatitis, with fewer data in chronic rhinosinusitis with nasal polyps and NSAID-exacerbated respiratory disease. The skin was the most frequently investigated site, followed by the sinonasal tract and gut. Across skin studies, dupilumab was consistently associated with reduced Staphylococcus aureus, increased microbial diversity, and enrichment of commensal taxa. Sinonasal studies suggested shifts toward more eubiotic microbial communities. Gut evidence was limited, although one study suggested modulation of tryptophan metabolism-related pathways. Dupilumab appears to exert compartment-specific and disease-dependent effects on the microbiome. The strongest evidence concerns the skin and sinonasal compartments, whereas gut microbiota changes remain poorly defined. Further prospective studies are needed to assess microbiota signatures as potential biomarkers of response.
References
- 1.Mari, P. V., Carriera, L., Saviano, A., Ricci, A., Coppola, A., Ielo, S., Lipsi, R., Dodaj, M., Gennari, F., Gullà, M., Stivalini, D., Pellegrino, M. G., Migneco, A., De Corso, E., & Ojetti, V. (2026). Impact of IL-4/IL-13 blockade with dupilumab on the microbiome in type 2 inflammatory diseases: A systematic review. Current Allergy and Asthma Reports. https://doi.org/10.2147/CCID.S393406
Related Research
Journal of tissue viability
Clinical decision support tools in wound management: A scoping review of existing and emerging tools.
2 Aug 2026
Lasers in medical science
Facial contour modulation and skin tightening using 40.68-MHz unipolar radiofrequency
27 July 2026
Clinical and experimental dermatology
Pemphigus vegetans: insights from a systematic review of the literature.
25 July 2026
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service